EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lipoprotein-associated phospholipase А2 as a biomarker and potential therapeutic target in post-stroke cognitive impairment

Chandra Wirawan, Desak Ketut Indrasari Utami, Agung Ayu Meidiary Anak, I Wayan Widyantara, I Putu Eka Widyadharma, Ketut Widyastuti

Annals of Clinical and Experimental Neurology · 30.06.2026 · 20 (2) · 70-76

DOI: 10.17816/acen.1462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Experimental Neurology, online erschienen am 30.06.2026. Verfasst von Chandra Wirawan und 5 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-stroke cognitive impairment (PSCI) is a major complication of cerebrovascular disease, spanning from mild cognitive impairment to dementia. PSCI pathogenesis involves complex mechanisms, including neuroinflammation, oxidative stress, and neuronal apoptosis. Recent studies have identified lipoprotein-associated phospholipase A2 (LP-PLA2) as a key enzyme in vascular inflammation and atherosclerosis, both of which are closely linked to post-stroke cognitive decline. LP-PLA2 contributes to PSCI pathogenesis via several pathways: (1) promoting vascular injury and neurodegeneration via inflammatory lipid metabolites such as lysophosphatidylcholine; (2) impairing the blood-brain barrier, leading to increased permeability and amyloid-β accumulation; and (3) inducing calcium-dependent neuronal apoptosis through oxidized fatty acids like arachidonic acid. These processes reduce cognitive reserve and neuroplasticity, thereby accelerating cognitive decline in ischemic stroke survivors. In addition, elevated LP-PLA2 levels have been associated with recurrent vascular events and unfavorable neurological outcomes, suggesting a role in ongoing post-stroke inflammation. Persistent activation of vascular inflammatory pathways may exacerbate cerebral small vessel disease, white matter damage, and synaptic dysfunction, which are critical determinants of long-term cognitive performance. The interaction between vascular injury and neurodegeneration further highlights the importance of inflammatory mediators in PSCI progression. Given its pathophysiological relevance, LP-PLA2 holds promise as a diagnostic biomarker and a therapeutic target for mitigating cognitive deterioration after stroke.

Zitieren

APA

Wirawan, C., Utami, D. K. I., Anak, A. A. M., Widyantara, I. W., Widyadharma, I. P. E., & Widyastuti, K. (2026). Lipoprotein-associated phospholipase А2 as a biomarker and potential therapeutic target in post-stroke cognitive impairment. Annals of Clinical and Experimental Neurology, 20(2), 70-76. https://doi.org/10.17816/acen.1462

Vancouver

Wirawan C, Utami DKI, Anak AAM, Widyantara IW, Widyadharma IPE, Widyastuti K. Lipoprotein-associated phospholipase А2 as a biomarker and potential therapeutic target in post-stroke cognitive impairment. Annals of Clinical and Experimental Neurology. 2026;20(2):70-76. doi:10.17816/acen.1462

BibTeX
@article{Wirawan2026,
  author = {Wirawan, Chandra and Utami, Desak Ketut Indrasari and Anak, Agung Ayu Meidiary and Widyantara, I Wayan and Widyadharma, I Putu Eka and Widyastuti, Ketut},
  title = {Lipoprotein-associated phospholipase А2 as a biomarker and potential therapeutic target in post-stroke cognitive impairment},
  journal = {Annals of Clinical and Experimental Neurology},
  year = {2026},
  volume = {20},
  number = {2},
  pages = {70--76},
  doi = {10.17816/acen.1462}
}
Kostenlos starten →